Esperion Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $403.1M | $332.3M | $116.3M | $75.5M | $78.4M |
| Selling, general & administrative | $165.8M | $163.1M | $142.5M | $109.1M | $185.0M |
| Research and development | $47.9M | $46.2M | $86.1M | $118.9M | $106.0M |
| Operating expenses | $342.9M | $277.9M | $271.9M | $255.0M | $305.2M |
| Operating income | $60.3M | $54.4M | -$155.6M | -$179.5M | -$226.7M |
| Interest expense | $84.6M | $59.3M | $59.0M | $56.8M | $46.4M |
| Pretax income | -$20.8M | -$51.7M | -$209.2M | — | — |
| Income tax expense | $1.8M | $0 | $0 | $0 | $0 |
| Net income | -$22.7M | -$51.7M | -$209.2M | -$233.7M | -$269.1M |
| Balance Sheet | |||||
| Cash and equivalents | $167.9M | $144.8M | $82.2M | $124.8M | $208.9M |
| Current assets | $462.6M | $338.0M | $201.1M | $246.7M | $329.0M |
| Total assets | $465.9M | $343.8M | $205.8M | $247.9M | $381.6M |
| Current liabilities | $300.8M | $246.2M | $156.2M | $92.3M | $73.4M |
| Total liabilities | $767.9M | $732.5M | $660.8M | $571.7M | $578.5M |
| Stockholders' equity | -$302.0M | -$388.7M | -$455.0M | -$323.8M | -$196.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$13.1M | -$23.7M | -$135.5M | -$174.8M | -$263.8M |
| Depreciation and amortization | $105,000 | $63,000 | $164,000 | $500,000 | $612,000 |
| Stock-based compensation | $9.9M | $12.0M | $12.0M | $15.2M | $24.3M |
| Capital expenditure | $0 | $317,000 | $0 | $0 | $0 |
| Free cash flow | -$13.1M | -$24.0M | -$135.5M | -$174.8M | -$263.8M |
| Share repurchases | — | — | — | — | $0 |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 257.4M · Free float 97.2%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.